---
title: "AmoyDx completes repurchase, with a total expenditure of 101 million yuan to repurchase 1.35% of shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229559901.md"
description: "According to the Zhitong Finance APP, AmoyDx announced that the company's share repurchase plan has been completed. As of February 25, 2025, the company has repurchased a total of 5.3748 million shares through centralized bidding, accounting for 1.35% of the company's current total share capital, with a total transaction amount of 101 million yuan (excluding transaction fees)"
datetime: "2025-02-25T10:11:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229559901.md)
  - [en](https://longbridge.com/en/news/229559901.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229559901.md)
generator: "portal-rs"
---

# AmoyDx completes repurchase, with a total expenditure of 101 million yuan to repurchase 1.35% of shares

According to the Zhitong Finance APP, AmoyDx (300685.SZ) announced that the company's share repurchase plan has been completed. As of February 25, 2025, the company has repurchased a total of 5.3748 million shares through centralized bidding, accounting for 1.35% of the company's current total share capital, with a total transaction amount of 101 million yuan (excluding transaction fees)

### Related Stocks

- [300685.CN](https://longbridge.com/en/quote/300685.CN.md)

## Related News & Research

- [Billionaire Stanley Druckenmiller Drops Sharp Take on Bonds](https://longbridge.com/en/news/296945329.md)
- [12:30 ETAPLA HEALTH'S 42ND ANNUAL AIDS WALK LOS ANGELES RETURNS TO WEST HOLLYWOOD ON OCTOBER 18, 2026](https://longbridge.com/en/news/296940018.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Seres-backed Aiva reportedly explores joining CATL battery swap network](https://longbridge.com/en/news/296920871.md)
- [ZEAL names York Scheunemann vice president of games](https://longbridge.com/en/news/296939615.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**